Related Experiment Videos
Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity
1Department of Pathology, Medical College of Pennsylvania, Philadelphia 19129.
Abstract:
Liarozole fumarate (R85,246), a novel benzimidazole derivative, reduced s.c. and bone metastasis tumor growth by the androgen-independent PC-3ML-B2 human prostatic carcinoma clone in SCID mice. The drug inhibited cell invasion of Matrigel in Boyden chamber chemotactic assays and the secretion of type IV collagenase. In vitro, liarozole failed to inhibit cell proliferation and cell attachment to various substrates (Matrigel, laminin, type IV collagen, and fibronectin). In vivo, the drug also blocked type IV collagenase production in established s.c. tumors. Liarozole has been postulated by others (R. De Coster, W. Wouters, R. Van Ginckel, D. End, et al. J. Steroid Biochem. Mol. Biol., 43: 197-201, 1992) to inhibit retinoic acid catabolism. Our data indicate that liarozole treatment can increase the tumor retinoic acid levels in vivo. Studies of retinoic acid revealed that the drug independently reduced tumor growth in vivo and inhibited cell invasion of Matrigel and the secretion of collagenase IV. Surprisingly, liarozole and retinoic acid failed to exhibit measurable synergistic activity both in vitro and in vivo. Taken together these data suggest that liarozole might inhibit retinoic acid catabolism in vivo and consequently have significant therapeutic value as an anti-prostatic tumor agent.
Insights
Liarozole fumarate, a novel benzimidazole, effectively reduced prostate tumor growth and metastasis in mice. It inhibited cancer cell invasion and collagenase secretion, suggesting therapeutic potential.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Prostate cancer metastasis remains a significant clinical challenge.
- Novel therapeutic agents targeting tumor growth and invasion are needed.
- Liarozole fumarate is a benzimidazole derivative with potential anti-cancer properties.
Purpose of the Study:
- To evaluate the efficacy of liarozole fumarate in inhibiting androgen-independent prostate cancer growth and metastasis.
- To investigate the mechanisms underlying liarozole's anti-tumor effects, including its impact on cell invasion and collagenase activity.
- To explore the relationship between liarozole, retinoic acid metabolism, and anti-prostatic tumor activity.
Main Methods:
- In vivo studies using SCID mice xenografted with human prostatic carcinoma cells (PC-3ML-B2).
- Boyden chamber chemotactic assays to assess cell invasion through Matrigel.
- Measurement of type IV collagenase secretion and production in vitro and in vivo.
- In vitro assays for cell proliferation and attachment to extracellular matrix components.
- Analysis of tumor retinoic acid levels following liarozole treatment.
Main Results:
- Liarozole fumarate significantly reduced subcutaneous and bone metastasis tumor growth in vivo.
- The drug inhibited prostate cancer cell invasion and type IV collagenase secretion.
- Liarozole did not affect cell proliferation or attachment in vitro.
- In vivo, liarozole blocked type IV collagenase production in established tumors.
- Liarozole treatment increased tumor retinoic acid levels in vivo.
- Retinoic acid alone also reduced tumor growth and inhibited cell invasion and collagenase IV secretion.
- No synergistic activity was observed between liarozole and retinoic acid.
Conclusions:
- Liarozole fumarate demonstrates significant anti-prostate tumor and anti-metastatic activity.
- The drug's mechanism involves inhibition of cancer cell invasion and type IV collagenase.
- Liarozole may exert its effects by inhibiting retinoic acid catabolism in vivo.
- These findings suggest liarozole fumarate holds therapeutic promise as an anti-prostatic tumor agent.